Silence Therapeutics to Participate in September Investor Conferences

Silence Therapeutics plc, a clinical-stage biotechnology company focused on developing innovative siRNA (small interfering RNA) therapies, has announced its upcoming participation in two notable investor conferences in September 2025. The events include the Morgan Stanley Global Healthcare Conference, where a fireside chat is scheduled for Tuesday, September 9, 2025, at 5:35 p.m. ET, and the H.C. Wainwright Global Investment Conference, taking place on Wednesday, September 10, 2025, at 12:00 p.m. ET. Investors interested in following these discussions can access the webcasts through the Investors section of Silence's official website.

Silence Therapeutics aims to transform lives by utilizing its proprietary mRNAi GOLD™ platform to develop precision medicines that silence disease-causing genes, particularly in the liver—a critical area with significant therapeutic potential. The company focuses on addressing high unmet medical needs in various therapeutic areas, including cardiovascular diseases, hematology, and rare diseases.

With a robust commitment to advancing innovative therapies, Silence Therapeutics is positioned at the forefront of biotechnology, leveraging its unique technologies to tackle some of the most pressing health challenges faced by patients today. Investors and stakeholders looking to gain insights into the company's strategic direction and ongoing projects should tune into the scheduled webcasts.

For further inquiries, Gem Hopkins, the Vice President and Head of Investor Relations and Corporate Communications at Silence Therapeutics, is available for contact via email or telephone.

For more detailed information about Silence Therapeutics and their approach to healthcare innovation, prospective investors and interested parties can visit the company's official website at https://www.silence-therapeutics.com/.

As of early September 2025, Silence Therapeutics plc (Nasdaq: SLN) is poised to leverage its participation in key investor conferences to enhance its visibility and attract potential investment. Engaging in high-profile events, such as the Morgan Stanley Global Healthcare Conference and the H.C. Wainwright Global Investment Conference, presents an opportunity for the company to showcase its innovative siRNA therapies and underline its commitment to addressing significant unmet medical needs.

Silence Therapeutics appears to be at an advantageous juncture, having developed its proprietary mRNAi GOLD™ platform, which is designed to precisely target and silence disease-associated genes, notably in areas like cardiovascular disease, hematology, and rare diseases. By addressing conditions that lack effective treatments, Silence not only positions itself as a pioneer in the biotechnology space but also differentiates its value proposition from competitors.

Investors should closely monitor the webcasts of these conferences, as management’s insights may provide crucial updates on pipeline progress, regulatory interactions, and partnerships that could shape the company’s trajectory. The potential for breakthroughs in high-impact therapeutic areas coupled with the systemic issues in healthcare further solidifies Silence’s relevance.

Given the volatility often seen in biotech stocks, establishing a position in Silence Therapeutics may align well with a longer-term investment strategy, particularly for those willing to accept some risk for potentially high rewards. However, potential investors should remain vigilant about market conditions, particularly in response to announcements made during these conferences. It's advisable to maintain a diversified portfolio to mitigate risks inherent in the biotech sector while keeping a keen eye on Silence’s advancements and strategic developments.